Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexiganan topical dose-ranging study for infected skin
IRCT20190924044863N3Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pexiganan in skin and soft tissue infections (SSTIs) (5 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Maximum tolerated dose. Started Jul 2025; status: completed.
02
Drugs
pexiganan
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on IRCT20190924044863N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190924044863N3.